The CTO-DENOVO study is a multicenter registry of consecutive patients with de novo coronary chronic total occlusions (CTO) undergoing successful CTO recanalization with the use of drug-coated balloon (DCB)-only strategy. The primary endpoint is target lesion failure at 6 months. The secondary endpoints are: 1) late lumen loss on follow-up angiography, and 2) minimal lumen area on follow-up intravascular ultrasound.

Inclusion Criteria:

• de novo coronary CTO undergoing successful recanalization with the use of DCB-only strategy at the occlusion site

Exclusion Criteria:

• de novo coronary CTO undergoing successful recanalization with the use of DES at the occlusion site
• in-stent CTO

Consecutive patients with de novo CTO undergoing successful PCI with the use of DCB-only strategy.